We reactivate the body’s own cells to fight disease
We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process.
Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age
This approach can be used to revitalize different cells throughout the body – we are researching its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis and ophthalmology.
Executive Team
A veteran of Fortune 500 enterprises and co-founder of three Silicon Valley startups, Anja has guided the evolution of companies and their products, taking companies public, repositioning enterprises, and managing development teams, clinical trials and partnerships. Anja’s successes have enabled four companies to sell themselves or their product lines to larger corporations. She received her bachelor’s degree from the University of South Carolina and a certificate of International Trade from the University of Paris, Sorbonne.
The technology at the foundation of Turn’s ERA™ platform was developed and patented in Vittorio’s Stanford University lab. An expert in stem cell biology and epigenetic reprogramming, he has worked in some of the world’s most prestigious academic institutions and is on the faculty of Stanford School of Medicine. He received his bachelor’s degree and doctorate from the University of Pavia and completed post-doctoral work at the Max Planck Institute for Molecular Biomedicine in Germany and Stanford.
An entrepreneur, philanthropist and investor, Sergio has worked with several biotechnologies designed to increase healthy lifespan. He is a senior advisor to numerous longevity biotech companies, helping them to evolve from academic organizations to commercial enterprises. Sergio is also managing director of the Methuselah Fund, one of the first longevity focused investor groups. He received his bachelor’s degree from the University of Maryland and a genetics and genomics certificate from Stanford University.
With more than two decades of financial leadership experience in the pharmaceutical industry, Ric understands the nuances of financial management, fundraising, road shows and initial public offerings. He has helped to guide six pharmaceutical companies – both large and small – as chief financial officer and managed balance sheets of up to $2 billion. He is also the Universal Insurance Holdings board audit committee chair. Ric received his bachelor’s degree from Arizona State University.
A corporate and patent attorney who completed postdoctoral work at Harvard Medical School, the VA Boston Healthcare System and Kyoto University, Devang has novel and practical perspectives on how to protect intellectual property here and internationally. As a U.S. patent examiner, he granted more than 130 pharmaceutical and biotechnology patents in a decade. He has also advised Global 500 companies, domestic and international startups, venture capital firms and universities on intellectual property and business issues.
A CMC expert who has founded two pharmaceutical companies and shaped the direction of several others, Mouhannad is an expert in CMC, the discipline of ensuring a therapeutic is safe, effective and consistent. He is responsible for planning and managing pharmaceutical, CMC analytical and pre-clinical activites. He received his doctorate in pharmaceutical science from the University of Kiel in Germany and completed post-doctoral work at the University of Kansas.
A veteran executive and dealmaker, Marie-Louise has helped companies develop license and distribution agreements and partnerships to boost sales and profitability. She has worked with multinational corporations like Royal Philips Electronics, Reed Elsevier and Aon Risk Solutions, as well as venture-backed biotechs. She serves on the supervisory boards of Royal Asscher Diamond Company and Plasmacure, a medical startup. Marie-Louise received her Economics degree from Fontys University and completed executive leadership studies at Harvard Business School, Babson College and the Rotterdam School of Management.
A proven drug developer with 30 years of pharmaceutical industry experience, Hans has helped bring 10 products to market, been involved with 13 INDs and holds 21 patents. This proficiency in commercializing laboratory science will be critical to his role leading the development of regenerative medicine therapies in dermatology, immunology, and ophthalmology. The veteran of more than a dozen dermatology and Immunology companies received his doctorate in Pharmaceutical Sciences from the University of Leiden in the Netherlands.